3: Sauvage (Costa Rica)
As described earlier in this proposed rule, CMS has observed that a number of NDC-9s of Part D rebatable drugs approved or licensed on or before October 1, 2021, do not have AMP reported in the period beginning January 1, 2021, and ending September 30, 2021, and a number of NDC-9s of subsequently approved drugs do not have AMP reported in the first calendar year following the drug's first marketed date
Can we stop this?"
When each of the activities was added, their requirements reflected clinical practice standards of the time, addressed areas of opportunity for fostering clinical practice improvements, and aligned with national public health priorities and CMS programs
Talk to your physician or dentist about nicotine substitutes
In response, several commenters advocated for CMS to continue to allow periodic assessments to be furnished audio-only when video is not available after the end of the PHE